Saturday 17 October 2026
Export TENX’s income statement to Excel — free account
Tenax Therapeutics, Inc.
TENX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 29.6% and free cash flow fell 125.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.36
0.15
−9.93%
Follow TENX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to April
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 38,720.00 | 9,920.00 | 1,648.00 | 1,744.00 | 400.00 | 1,616.00 | 128.00 | 12.08 | 2.77 | 4.63 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 107,840.00 | 84,800.00 | 20,208.00 | 4,464.00 | 4,544.00 | 5,888.00 | 2,334.40 | 344.00 | 22.88 | 14.22 | |||||
| People | |||||||||||||||
| People | Employees | 11 | 8 | 10 | 10 | 10 | 9 | 8 | 6 | 6 | 16 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (44) | (9) | (7) | (8) | (10) | (32) | (11) | (8) | (18) | (53) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (44) | (9) | (14) | (8) | (10) | (32) | (11) | (8) | (18) | (53) | |||||
| Depreciation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (49,920.00) | (10,017.20) | (14,464.00) | (2,160.00) | (1,520.57) | (2,528.00) | (560.16) | (31.04) | (1.15) | (1.34) | |||||
| Cash flow | (17,634.78) | (13,489.44) | (5,499.50) | (1,937.49) | (1,426.60) | (841.57) | (618.95) | (23.81) | (0.97) | (0.91) | |||||
| Capex | 80.11 | (5.00) | (7.60) | (0.92) | (0.54) | (0.41) | (0.12) | 0.01 | 0.00 | 0.00 | |||||
| Free cash flow | (17,554.67) | (13,494.44) | (5,507.10) | (1,938.41) | (1,427.14) | (841.98) | (619.07) | (23.79) | (0.97) | (0.91) | |||||
| Book value | 19,045.44 | 9,868.78 | 11,771.50 | 967.31 | 711.63 | 329.05 | 81.13 | 32.65 | 6.02 | 2.48 | |||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 39 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (16) | (12) | (5) | (8) | (9) | (11) | (11) | (6) | (15) | (36) | ||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | |||||
| Free cash flow | (16) | (12) | (6) | (8) | (9) | (11) | (11) | (6) | (15) | (36) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 7 | 7 | 12 | 4 | 5 | 4 | 1 | 8 | 92 | 97 | ||||
| Total debt | — | — | — | 0 | 0 | 0 | 1 | — | — | — | |||||
| Net debt | (13) | (8) | (13) | (5) | (7) | (6) | (2) | (10) | (95) | (98) | |||||
| Shareholders’ equity | 17 | 9 | 12 | 4 | 5 | 4 | 1 | 8 | 92 | 97 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (91.20) | (53.20) | (121.79) | (85.21) | (148.88) | (505.01) | (235.14) | (102.20) | (32.48) | (52.36) | ||||
| ROIC | (852.44) | (498.28) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | (113.26) | (67.94) | (136.97) | (108.01) | (234.61) | (732.21) | (385.12) | (160.80) | (35.17) | (55.64) | |||||
Negative figures in brackets.
Fiscal years to Apr 2015 · latest quarter Jun 2015
Charts ten years each
Tenax Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| XLO Xilio Therapeutics, Inc. | $59.4M | — (loss-making) | — (loss-making) | +131.22% (above 0%: growing) | n/m | −26.23% (below 0%: shrinking) | 100.00% | (18.68%) | Compare |
| GANX Gain Therapeutics, Inc. | $58.1M | — (loss-making) | — (loss-making) | +27.78% (above 0%: growing) | n/m | +8.22% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR | $57.1M | — (loss-making) | — (loss-making) | +296.56% (above 0%: growing) | n/m | −23.48% (below 0%: shrinking) | 100.00% | (635.98%) | Compare |
| TENX Tenax Therapeutics, Inc. | $56.5M | — (loss-making) | — | −77.98% (below 0%: shrinking) | n/m | −125.93% (below 0%: shrinking) | 0.00% | 0.00% | |
| ALPS Alps Group Inc. | $56.4M | — (loss-making) | — | — | n/m | −26.48% (below 0%: shrinking) | — | 0.00% | Compare |
| ELOX Senesco Technologies Inc. | $55.3M | — (loss-making) | — | — | n/m | −144.34% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| GUTS Fractyl Health, Inc. | $55.2M | — (loss-making) | — (loss-making) | −57.14% (below 0%: shrinking) | n/m | +25.34% (above 0%: growing) | 100.00% | 0.00% | Compare |
| GOSS Gossamer Bio, Inc. | $54.3M | — (loss-making) | — (loss-making) | −19.59% (below 0%: shrinking) | n/m | +16.32% (above 0%: growing) | 100.00% | (282.25%) | Compare |
| RNTX Rein Therapeutics Inc. | $54.2M | — (loss-making) | — | — | n/m | −34.62% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $55.9M | — | — | +27.78% | — | −24.85% | 100.00% | 0.00% |
Tenax Therapeutics, Inc. (TENX) key facts
- Tenax Therapeutics, Inc. (TENX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, TENX traded at $1.36, a market capitalization of $56.5 million.
- Return on equity was −55.6% and debt-to-equity 0.00.